Analysts’ Weekly Ratings Updates for Solventum (SOLV)

Several analysts have recently updated their ratings and price targets for Solventum (NYSE: SOLV):

• 7/13/2026 – Solventum had its “buy” rating reaffirmed by BTIG Research. They now have a $91.00 price target on the stock.
• 7/8/2026 – Solventum is now covered by BMO Capital Markets. They set a “market perform” rating and a $81.00 price target on the stock.
• 7/8/2026 – Solventum was upgraded by BMO Capital Markets to “hold”.
• 6/26/2026 – Solventum was downgraded by Weiss Ratings from “hold (c+)” to “hold (c)”.
• 6/11/2026 – Solventum was upgraded by Weiss Ratings from “hold (c)” to “hold (c+)”.

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.

See Also

• Five stocks we like better than Solventum
• Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street
• Revving Up Returns: Big Banks Race Through the Rate Plateau
• Why Uber’s Biggest Deal Yet Could Unlock Its Next Growth Phase
• Why Microsoft Is Playing a Different AI Game Than Big Tech—and Cash Flow Is the Test